- Worldwide Delivery4-7 business days
- Quality GuaranteedOnly original products
- Bonus pillsSave up to 80%
- 24/7 SupportOur team of pharmacists is available 24/7 to help you
Patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases may be prescribed Ofev to slow the decline in lung function. Its active ingredient, nintedanib, targets signalling pathways involved in fibrotic disease and is taken orally as a capsule under specialist supervision.
Product information
Patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases may be prescribed Ofev to slow the decline in lung function. Its active ingredient, nintedanib, targets signalling pathways involved in fibrotic disease and is taken orally as a capsule under specialist supervision.
How it affects the body
Nintedanib blocks signalling through vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptors. These pathways can stimulate abnormal cell activity, blood-vessel changes, and fibrosis. By inhibiting them, Ofev aims to reduce the rate at which lung function declines.
Ingredients
Ofev contains nintedanib, an intracellular tyrosine kinase inhibitor used in selected progressive lung diseases. The capsules are taken by mouth with food. Ofev is intended to slow disease progression; it does not remove established scar tissue or restore lung tissue that has already been damaged.
| Pharmaceutical fact | Ofev |
|---|---|
| Active ingredient and class | Nintedanib; tyrosine kinase inhibitor |
| Dosage form and route | Oral capsule |
| Main treatment areas | Idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease, systemic sclerosis-associated interstitial lung disease |
Idiopathic pulmonary fibrosis is a chronic condition in which scar tissue develops in the lungs without an identified cause. Progressive fibrosing interstitial lung disease describes several disorders that continue to produce fibrosis and loss of lung capacity despite initial treatment. Systemic sclerosis-associated interstitial lung disease occurs when systemic sclerosis affects the lung tissue.
Nintedanib Pharmacological Action
Nintedanib blocks signalling through vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptors. These pathways can stimulate abnormal cell activity, blood-vessel changes, and fibrosis. By inhibiting them, Ofev aims to reduce the rate at which lung function declines.
The treatment goal is measured over time. A person may still experience breathlessness or reduced exercise tolerance while the medicine slows further deterioration. The European Medicines Agency describes nintedanib as a treatment for progressive fibrosing lung disease rather than a cure for pulmonary fibrosis [1].
Clinical Conditions Treated With Ofev
Specialists may consider Ofev for:
- Idiopathic pulmonary fibrosis in adults.
- Chronic fibrosing interstitial lung disease with a progressive phenotype.
- Systemic sclerosis-associated interstitial lung disease.
Treatment selection depends on the diagnosis, lung-function pattern, liver health, bleeding risk, other medicines, and the patient’s ability to tolerate gastrointestinal effects. A pulmonologist usually assesses whether the pattern of progression fits the approved use of nintedanib.
Dosage and administration
Ofev is supplied as an oral capsule. The appropriate strength and daily schedule are selected individually, taking age, other medicines, liver function, and overall health into account. The dispensing presentation may vary according to the approved product information for the relevant market.
Swallow each capsule whole with liquid and food unless the treating clinician gives different instructions.
Capsule Handling Requirements
Do not open, chew, crush, or break the capsule. The capsule should remain intact so the medicine can be taken as intended and contact with the contents is minimised.
Capsule colour is not a dosing guide. When a different presentation is dispensed, identify it by the medicine name and written instructions rather than appearance alone.
Ofev Dosage and Administration
The usual adult regimen is prescribed as two oral doses taken at approximately 12-hour intervals with food. The exact dose is decided individually, taking age, other medicines, liver function, and health conditions into account.
- Take Ofev with a meal.
- Swallow the capsule whole with liquid.
- Keep the doses as evenly spaced as practical.
- Follow the prescribed strength and schedule.
- Do not change the dose without the treating clinician.
- Do not double the next dose after a missed dose.
- Report persistent diarrhoea, vomiting, dehydration, or unusual bleeding promptly.
A clinician may reduce the dose temporarily, interrupt treatment, or stop treatment when adverse effects are significant. A lower prescribed dose can be a safety adjustment rather than evidence that treatment has failed.
Liver-function tests are generally obtained before treatment and repeated during therapy. The FDA prescribing information also highlights liver injury, diarrhoea, bleeding, cardiovascular events, and gastrointestinal perforation as clinically relevant risks requiring assessment [2].
Food and Timing Instructions
Food helps reduce gastrointestinal intolerance for many patients. A practical schedule might place one dose with breakfast and another with the evening meal, although the prescribed timing should fit the individual’s routine.
Avoid taking two doses close together to compensate for a timing error. If a dose is forgotten, follow the missed-dose instructions given by the treating team rather than improvising a replacement schedule.
Dose Adjustments and Treatment Interruptions
Dose reduction or a short interruption may be used when diarrhoea, vomiting, liver-test abnormalities, or other adverse effects make the usual regimen difficult to tolerate. These changes require clinical direction.
Do not restart after an interruption using a previous schedule without confirming the plan. The correct restart point can depend on the reason for interruption and the patient’s laboratory results.
When not to use it
- Significant liver impairment or active liver disease.
- Previous serious reaction to nintedanib or a capsule component.
- Pregnancy or the possibility of pregnancy.
- Breastfeeding.
- Active bleeding or a high bleeding risk.
- Anticoagulant or antiplatelet treatment.
- Recent surgery or planned major surgery.
- Cardiovascular disease or uncontrolled blood pressure.
- Previous gastrointestinal perforation or a condition that increases this risk.
- Severe, persistent diarrhoea or poor nutritional status.
When this is not for you
Ofev is not suitable for everyone. NOT for you if a specialist identifies a contraindication, an unacceptable interaction risk, or an inability to complete required monitoring; discuss alternative treatment with the specialist. A specialist should review the following before treatment:
- Significant liver impairment or active liver disease.
- Previous serious reaction to nintedanib or a capsule component.
- Pregnancy or the possibility of pregnancy.
- Breastfeeding.
- Active bleeding or a high bleeding risk.
- Anticoagulant or antiplatelet treatment.
- Recent surgery or planned major surgery.
- Cardiovascular disease or uncontrolled blood pressure.
- Previous gastrointestinal perforation or a condition that increases this risk.
- Severe, persistent diarrhoea or poor nutritional status.
Pregnancy and Contraception
Nintedanib may harm an unborn baby. Pregnancy should be avoided during treatment, and contraceptive planning should be individualised. Contact the treating clinician promptly if pregnancy occurs or is suspected.
The EMA product information describes reproductive toxicity concerns with nintedanib [3]. Do not stop prescribed contraception or begin a new contraceptive medicine without reviewing the choice with a qualified clinician, because interactions and individual risks differ.
Breastfeeding Considerations
It is not known whether nintedanib passes into human milk in clinically relevant amounts. Breastfeeding decisions require a direct assessment of the potential benefit of treatment, the importance of breastfeeding, and possible infant exposure.
Do not assume that a lack of symptoms in the infant proves that exposure is harmless. The treatment team should provide a specific plan before therapy begins.
Liver, Bleeding and Surgery Precautions
Report black stools, vomiting blood, unexplained bruising, or persistent nosebleeds. Tell the surgeon and anaesthesia team about Ofev before an operation, because treatment may need planned interruption around surgery.
Do not stop anticoagulants, aspirin, or clopidogrel independently. Stopping them suddenly can create a separate risk of thrombosis, stroke, or cardiovascular events.
Possible side effects
The most frequently discussed adverse effects involve the digestive system. Diarrhoea, nausea, abdominal pain, vomiting, reduced appetite, and weight loss can affect daily activities and may lead to dose adjustment.
| More common effects | Urgent warning signs |
|---|---|
| Diarrhoea, nausea, abdominal discomfort, vomiting, reduced appetite, weight loss | Severe or persistent diarrhoea, dehydration, jaundice, unusual bleeding, severe abdominal pain, chest pain, facial swelling, or breathing difficulty |
The frequency of adverse effects varies between idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease, and systemic sclerosis-associated lung disease. The approved product information should guide interpretation of frequency categories.
Gastrointestinal Effects and Hydration
Repeated watery stools can cause dehydration, dizziness, weakness, and worsening kidney function. Patients should report persistent diarrhoea early because treatment interruption, fluid replacement, or a dose adjustment may be needed.
Do not use frequent anti-diarrhoeal medicines as a substitute for reporting ongoing symptoms. Severe abdominal pain, fever, bloody stools, or inability to keep fluids down needs urgent assessment.
Liver Injury and Laboratory Monitoring
Nintedanib can increase liver enzymes, including ALT and AST, and can affect bilirubin. Possible liver-injury symptoms include yellowing of the skin or eyes, dark urine, pale stools, marked tiredness, nausea, or pain beneath the right ribs.
Liver tests are checked before treatment and during therapy. People with existing liver disease may require a different approach, closer monitoring, or avoidance of treatment depending on the severity.
Bleeding, Cardiovascular and Gastrointestinal Risks
Nintedanib may increase concern about bleeding, especially in people taking anticoagulants or antiplatelet medicines. Unexplained bruising, persistent nosebleeds, black stools, vomiting blood, or blood in the urine requires prompt medical attention.
Patients with coronary artery disease, recent heart attack, stroke risk, uncontrolled hypertension, previous gastrointestinal perforation, or recent major surgery need an individual risk assessment. Chest pain, sudden weakness, severe abdominal pain, or collapse warrants emergency care.
Therapeutic indications
Idiopathic pulmonary fibrosis is a chronic condition in which scar tissue develops in the lungs without an identified cause. Progressive fibrosing interstitial lung disease describes several disorders that continue to produce fibrosis and loss of lung capacity despite initial treatment. Systemic sclerosis-associated interstitial lung disease occurs when systemic sclerosis affects the lung tissue.
Specialists may consider Ofev for:
- Idiopathic pulmonary fibrosis in adults.
- Chronic fibrosing interstitial lung disease with a progressive phenotype.
- Systemic sclerosis-associated interstitial lung disease.
Comparison
Ofev is an oral, single-ingredient antifibrotic treatment that targets signalling pathways involved in fibrotic disease, unlike approaches focused only on symptom relief.
Common mistakes
Mistake: taking the capsule without food
Food is part of the administration routine. Taking Ofev on an empty stomach may worsen nausea or diarrhoea for some patients.
Mistake: opening or chewing the capsule
The capsule should remain intact. Opening it can affect accurate administration and increase direct contact with nintedanib.
Mistake: doubling after a missed dose
A double dose does not restore the treatment schedule and may increase adverse effects. Resume the next scheduled dose according to the prescribed instructions.
Mistake: ignoring persistent diarrhoea
Repeated watery stools can lead to dehydration and weight loss. Early reporting may allow a planned interruption or dose adjustment before the problem becomes severe.
Mistake: stopping anticoagulants independently
Anticoagulants and antiplatelet medicines require coordinated review. Stopping them without direction may create a serious clotting risk.
Mistake: assuming a lower dose means treatment failure
A dose adjustment may be used to improve tolerability while maintaining treatment. The change should be judged by the clinician using symptoms, liver tests, weight, and lung-function results.
The WHO describes medication safety as dependent on accurate communication about all medicines, including non-prescription products and supplements [4].
What doctors say
In clinical practice, pulmonologists usually set expectations early: Ofev is used to slow progression, and its benefit may not be felt as an immediate change in breathing. The decision to continue treatment depends on the balance between disease progression, tolerability, laboratory findings, and the patient’s goals. Monitoring is part of the treatment plan. Patients should report new or worsening adverse effects promptly. Lung-function results help guide review.
Doctors often focus on details patients may overlook. A small fall in weight can signal poor intake from nausea or diarrhoea. A rise in liver enzymes can appear before jaundice. A medication list that omits occasional ibuprofen can hide an important bleeding concern.
Specialist follow-up also helps distinguish disease progression from treatment intolerance. Worsening breathlessness does not automatically mean that the medicine has failed, while stable symptoms do not replace lung-function testing.
Common questions
Can Ofev affect driving, concentration, or work with machinery?
Ofev is not generally described as a sedative, but diarrhoea, vomiting, weakness, dehydration, nausea, or dizziness can reduce concentration and make driving unsafe. The FDA product information reviewed in 2024 lists gastrointestinal adverse effects that may interfere with daily activities. Avoid driving or operating machinery if symptoms affect alertness, balance, vision, or strength.
What is the best time of day to take Ofev?
The capsules are generally taken with food at evenly spaced times, often morning and evening. EMA product information available in 2024 supports administration with food to improve tolerability. A consistent schedule linked to meals is easier to remember, but the prescribed timing takes priority.
Can Ofev be used during pregnancy or breastfeeding?
Nintedanib may harm fetal development, so pregnancy requires immediate contact with the treating clinician. WHO reproductive-health guidance in 2023 supports individual counselling when a medicine may affect pregnancy or breastfeeding. Breastfeeding should also be reviewed because the extent of nintedanib transfer into human milk is uncertain.
What should happen if the expected result does not come?
Ofev is intended to slow loss of lung function, so lack of immediate symptom improvement does not by itself show that treatment is ineffective. Specialist guidance from the American Thoracic Society in 2022 assesses response through lung-function trends, symptoms, weight, and tolerability. Do not increase the dose or stop treatment independently when improvement is not obvious.
What should happen after a missed dose or application?
Skip a missed dose when the next scheduled dose is close, then continue at the usual time. Do not take an extra capsule to compensate. The EMA product information reviewed in 2024 also supports avoiding a double dose after a missed administration, while persistent vomiting or extra dosing requires individual advice.
Can the Ofev capsule be split, crushed, or chewed?
The capsule should be swallowed whole with liquid and food. Do not split, crush, chew, or open it because this can make administration inaccurate and increase direct contact with the contents. MOHAP medication-safety information published in 2023 supports preserving the intended dosage form unless a product-specific instruction states otherwise.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Sources
- European Medicines Agency (2024). Ofev: European public assessment report and product information.
- U.S. Food and Drug Administration (2024). Ofev (nintedanib) Prescribing Information.
- European Medicines Agency (2024). Ofev product information: pregnancy, lactation and reproductive toxicity sections.
- World Health Organization (2023). Medication Without Harm: Global Patient Safety Action Plan 2021–2030.